The biotechnology start-up Nuage Therapeutics, a member of Catalonia.health, has secured €2.7 million in funding from the Spanish State Research Agency (AEI) of the Ministry of Science, Innovation and Universities to advance a research project focused on the development of a new drug for small cell lung cancer (SCLC), subtype SCLC-A, one of the most aggressive forms of this disease.
The project is being carried out in collaboration with the Spanish National Cancer Research Centre (CNIO), the European Molecular Biology Laboratory in Barcelona (EMBL Barcelona) and the Vall d’Hebron Institute of Oncology (VHIO).
The consortium has already begun developing the innovative therapy NTX-A, a pioneering drug targeting the ASCL1 protein, which plays a key role in the onset and progression of the SCLC-A subtype, characterised by rapid tumour progression and particularly aggressive clinical behaviour. This initiative aims to provide a new therapeutic option for patients with limited treatment alternatives and to contribute to advances in precision therapies for aggressive cancers.
In addition to its focus on NTX-A for SCLC-A, the company is leading complementary projects to identify effective modulators of other intrinsically disordered proteins involved in hard-to-treat diseases.
According to Stuart Hughes, CEO of Nuage Therapeutics, “This grant validates our approach to targeting intrinsically disordered proteins (IDPs) and accelerates our mission to drive a new generation of transformative precision therapies for aggressive cancers with limited treatment options.”
Comments